sarcosine dithiocarbamate has been researched along with Leukemia L 1210 in 1 studies
sarcosine dithiocarbamate: protects against toxicity of alkylating agents
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osswald, H | 1 |
| Frank, N | 1 |
1 other study available for sarcosine dithiocarbamate and Leukemia L 1210
| Article | Year |
|---|---|
Sacrosine- and prolinedithiocarbamate pretreatment increases the therapeutic efficacy of doxorubicin, methotrexate, teniposide, mitoxantrone or cyclohexylchloroethylnitrosourea in leukemia L1210.
Topics: Animals; Antineoplastic Agents; Cysteine; Doxorubicin; Drug Synergism; Female; Leukemia L1210; Lomus | 1990 |